Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10245099 | 0.90 | KMT2A (0.55) | KMT2ARAB9ANPC1POLBTDP1 | |
| SCHEMBL8367257 | 0.81 | RAB9A (0.51) | KMT2ARAB9ANPC1POLBTDP1 | |
| SCHEMBL21790566 | 0.81 | RAB9A (0.44) | KMT2ARAB9ANPC1POLBTDP1 | |
| SCHEMBL680486 | 0.81 | KMT2A (0.57) | KMT2ARAB9ANPC1POLBTDP1 | |
| SCHEMBL12788408 | 0.81 | KMT2A (0.47) | KMT2ARAB9ANPC1POLBTDP1 | |
| SCHEMBL4394146 | 0.80 | KMT2A (0.52) | KMT2ARAB9ANPC1POLBTDP1 | |
| SCHEMBL13811574 | 0.79 | PIK3CD (0.48) | KMT2AALDH1A1 | |
| SCHEMBL13612784 | 0.78 | RAB9A (0.56) | KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12259054 | 0.78 | PIK3CD (0.53) | KMT2ARAB9ANPC1POLBTDP1 | |
| SCHEMBL5424673 | 0.78 | PIK3CD (0.54) | KMT2APOLBTDP1MALT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | KMT2A 1452/4885RAB9A 1513/4885NPC1 3672/4885 |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | NPSR1, HRH4, OPRL1 | KMT2A 711/4885RAB9A 1714/4885NPC1 920/4885 |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | KMT2A 3443/4885RAB9A 3778/4885NPC1 4242/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | KMT2A 1406/4885RAB9A 1490/4885NPC1 3877/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | KMT2A 2532/4885RAB9A 1884/4885NPC1 381/4885 |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | KMT2A 4225/4885RAB9A 2441/4885NPC1 2824/4885 |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | KMT2A 3443/4885RAB9A 3778/4885NPC1 4242/4885 |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | SIGMAR1, TMEM97, OPRM1 | KMT2A 3188/4885RAB9A 4494/4885NPC1 2270/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | KMT2A 1452/4885RAB9A 1513/4885NPC1 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.